Sciex and the National University of Singapore Collaborate
Sciex (Massachusetts, USA) has signed a Memorandum of Understanding with the National University of Singapore to promote the research of oncology biomarker discovery and development.
Sciex (Massachusetts, USA) has signed a Memorandum of Understanding with the National University of Singapore to promote the research of oncology biomarker discovery and development. The partnership will see Sciex enable workshops on qualitative and quantitative proteomics to educate the regional research community on alternative methods for proteomics. Researchers will also collaborate to develop mass spectrometry approaches for protein and metabolite profiling of zebrafish serum.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
